« Back
Home /
Eltrombopag

Eltrombopag

Item no.	HY-15306-100mg
Manufacturer	MedChem Express
CASRN	496775-61-2
Amount	100 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 1 mg 50 mg 5 mg
Category	Oncology Neuroscience Neuroinflammation Inhibitors & Compound Libraries Small Molecules By Organ Heart & Blood Cancer Bone Cancer
Type	Inhibitors
Specific against	other
Purity	99.94
Citations	[1]Erickson-Miller CL, et al. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells. 2009 Feb;27(2):424-30.\|[2]Erickson-Miller CL, et al. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol. 2005 Jan;33(1):85-93.\|[3]Lee H, et al. Repurposing Eltrombopag for Multidrug Resistant Staphylococcus aureus Infections. Antibiotics (Basel). 2021 Nov 9;10(11):1372.\|[4]Juan Zhu, et al. Identification of Eltrombopag as a Repurposing Drug Against Staphylococcus epidermidis and its Biofilms. Curr Microbiol. 2021 Feb 21.\|[5]Kurokawa T, et al. The Eltrombopag antitumor effect on hepatocellular carcinoma. Int J Oncol. 2015 Nov;47(5):1696-702. ACS Nano. 2024 Aug 28.\|Alzheimers Res Ther. 2024 Jun 3;16(1):121.\|bioRxiv. 2025 March 03.\|Blood Adv. 2017 Feb 28;1(7):468-476.\|BMC Cancer. 2020 Nov 30;20(1):1171.\|Cell Death Discov. 2024 Oct 26;10(1):453.\|Cells. 2022, 11(3), 319.\|Curr Microbiol. 2021 Feb 21.\|Eur J Pharmacol. 2024 Oct 29:177086.\|J Pharm Biomed Anal. 235, 25 October 2023, 115683\|J Thromb Haemost. 2022 May 27.\|J Transl Med. 2025 Jan 22;23(1):103.\|Virology. 2023 Jun 21.\|Viruses. 2019 Apr 25;11(4):385. \|Eur J Clin Pharmacol. 2022 Aug 3.\|Front Pharmacol. 2020 Nov 16;11:582625.
Smiles	O=C(C1=CC(C2=CC=CC(N/N=C3C(C)=NN(C4=CC=C(C)C(C)=C4)C/3=O)=C2O)=CC=C1)O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	SB-497115
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	COVID-19-immunoregulation
Manufacturer - Targets	Apoptosis; Bacterial; Thrombopoietin Receptor
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	442.47
Product Description	Eltrombopag (SB-497115) is an orally active thrombopoietin receptor nonpeptide agonist. Eltrombopag owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. Eltrombopag can be used for the research of cardiovascular. Eltrombopag also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. Eltrombopag can induce apoptosis in hepatocellular carcinomab (HCC) as well[1][2][3][4][5].
Manufacturer - Research Area	Cancer; Infection; Cardiovascular Disease
Solubility	DMSO: 8.33 mg/mL (ultrasonic)
Manufacturer - Pathway	Anti-infection; Apoptosis; Immunology/Inflammation
Clinical information	Launched

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-15306-100mg-safety-datasheet.pdf